Literature DB >> 24682649

Regional delivery of oncolytic vaccinia virus: it's time for clinical trials.

Stephanie Downs-Canner1, David L Bartlett.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24682649      PMCID： PMC4262111          DOI： 10.1245/s10434-014-3660-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  10 in total

1.  A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases.

Authors:  Kristopher J Kimball; Meredith A Preuss; Mack N Barnes; Minghui Wang; Gene P Siegal; Wen Wan; Huichien Kuo; Souheil Saddekni; Cecil R Stockard; William E Grizzle; Raymond D Harris; Rosemarie Aurigemma; David T Curiel; Ronald D Alvarez
Journal:  Clin Cancer Res       Date:  2010-10-26       Impact factor: 12.531

2.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.

Authors:  J A McCart; J M Ward; J Lee; Y Hu; H R Alexander; S K Libutti; B Moss; D L Bartlett
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

3.  Targeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenoviruses.

Authors:  Zeng B Zhu; Sharmila K Makhija; Baogen Lu; Minghui Wang; Shuyi Wang; Koichi Takayama; Gene P Siegal; Paul N Reynolds; David T Curiel
Journal:  J Thorac Oncol       Date:  2006-09       Impact factor: 15.609

4.  Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.

Authors:  P A Vasey; L N Shulman; S Campos; J Davis; M Gore; S Johnston; D H Kirn; V O'Neill; N Siddiqui; M V Seiden; S B Kaye
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

5.  Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis.

Authors:  Deepa Magge; Mazen S Zenati; Frances Austin; Arun Mavanur; Magesh Sathaiah; Lekshmi Ramalingam; Heather Jones; Amer H Zureikat; Matthew Holtzman; Steven Ahrendt; James Pingpank; Herbert J Zeh; David L Bartlett; Haroon A Choudry
Journal:  Ann Surg Oncol       Date:  2013-12-10       Impact factor: 5.344

6.  An oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesothelioma.

Authors:  Laurence J Belin; Justin W Ady; Christina Lewis; Drew Marano; Sepideh Gholami; Kelly Mojica; Clarisse Eveno; Valerie Longo; Pat B Zanzonico; Nanhai G Chen; Aladar A Szalay; Yuman Fong
Journal:  Surgery       Date:  2013-07-23       Impact factor: 3.982

7.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Authors:  Jeong Heo; Tony Reid; Leyo Ruo; Caroline J Breitbach; Steven Rose; Mark Bloomston; Mong Cho; Ho Yeong Lim; Hyun Cheol Chung; Chang Won Kim; James Burke; Riccardo Lencioni; Theresa Hickman; Anne Moon; Yeon Sook Lee; Mi Kyeong Kim; Manijeh Daneshmand; Kara Dubois; Lara Longpre; Minhtran Ngo; Cliona Rooney; John C Bell; Byung-Geon Rhee; Richard Patt; Tae-Ho Hwang; David H Kirn
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

8.  A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer.

Authors:  Kenneth H Kim; Igor P Dmitriev; Souheil Saddekni; Elena A Kashentseva; Raymond D Harris; Rosemarie Aurigemma; Sejong Bae; Karan P Singh; Gene P Siegal; David T Curiel; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-06-10       Impact factor: 5.482

9.  Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.

Authors:  Anne Gauvrit; Samantha Brandler; Carole Sapede-Peroz; Nicolas Boisgerault; Frédéric Tangy; Marc Gregoire
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

10.  Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.

Authors:  Evanthia Galanis; Lynn C Hartmann; William A Cliby; Harry J Long; Prema P Peethambaram; Brigitte A Barrette; Judith S Kaur; Paul J Haluska; Ileana Aderca; Paula J Zollman; Jeff A Sloan; Gary Keeney; Pamela J Atherton; Karl C Podratz; Sean C Dowdy; C Robert Stanhope; Timothy O Wilson; Mark J Federspiel; Kah-Whye Peng; Stephen J Russell
Journal:  Cancer Res       Date:  2010-01-26       Impact factor: 12.701
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.